Michelle Laflamme

Access Vascular, Inc. engages in the development and manufacture of medical devices. It provides hydrogel-based medical devices, such as catheter and stenst to improve venous access. The firm also improves peripherally inserted central catheter, hemodialysis, implantable ports, and drug delivery devices. The company was founded by James Biggins in 2015 and is headquartered in Bedford, MA.

Panthera Dental Inc. engages in prosthetic implant solutions and dental sleep appliances. Its products include metal implant bar, integrated bar, diamart, ReBourke, Copywax, Angulated Screw Channel, and Components and Attachment. The company was founded by Bernard Robichaud, Gabriel Robichaud, and Beatrice Robichaud in 2011 and is headquartered in Quebec, Canada.

VG Partners is a private equity investment firm. The private company is based in Toronto, Canada. and has subsidiaries in Canada.

AurKa Pharma, Inc. develops medication for cancer treatment. The company was founded by Caroline Fortier and is headquartered in Montreal, Canada.

Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden.

Modulate Therapeutics, Inc. develops a medicine compound designed to re-engage the immune system in order to recognize and eradicate neoplastic disease. The company was founded by September 29, 2015 and is headquartered in Montréal, Canada.

CDP Capital Private Equity (CDPQ) is a private equity subsidiary of The Caisse de dépôt et placement du Québec founded in 1995. The firm is headquartered in Montréal with additional office in London.

Ixchelsis Ltd. develops oxytocin receptor antagonist for the treatment of premature ejaculation. It operates as a biotechnology company. The firm's product in pipeline IX-01 treats the male sexual health indication and premature ejaculation. The company was founded on July 27, 2011 by Gary John Muirhead, Lizbeth Anne Littlewood, Ian Howard Osterloh and Karl Richard Gibson and is headquartered in Sandwich, the United Kingdom.

LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada.

Cita Neuro Pharmaceuticals, Inc. develops and commercializes small molecule drugs. Its clinical drug portfolio consists of drugs for Parkinson's disease and neuropathic pain. Cita Neuro Pharmaceuticals was founded in 1997 by Brian Bennett, Roland Boegman, Khem Jha-mandas, James Reynolds and Gregory Thatcher and is headquartered in Mississauga, Canada.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials.

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.